Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients

被引：0
|
作者：
Gervasini, G.
García-Martín, E.
Ladero, J. M.
Pizarro, R.
Sastre, J.
Martínez, C.
García, M.
Díaz-Rubio, M.
Agúndez, J. A. G.
机构：
[1] Univ Extremadura, Dept Pharmacol & Psychiat, E-06071 Badajoz, Spain
[2] Univ Extremadura, Dept Biochem & Mol Biol & Genet, E-06071 Badajoz, Spain
[3] Univ Complutense Madrid, Hosp Clin Carlos, Gastroenterol Serv, Madrid, Spain
[4] Univ Complutense Madrid, Hosp Clin Carlos, Serv Oncol, Madrid, Spain
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2006年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [21] Analysis of genotype, MRNA and protein expression of CYP3A4 and CYP3A5 in human liver
    Czerwinski, M
    Lyon, K
    Mudra, D
    Madan, A
    van Schaik, R
    Gaedigk, A
    Parkinson, A
    DRUG METABOLISM REVIEWS, 2002, 34 : 149 - 149
  • [22] CYP3A5 and not CYP3A4 is present in peripheral blood.
    Janardan, SK
    Lown, KS
    SchmiedlinRen, P
    Watkins, PB
    GASTROENTEROLOGY, 1996, 110 (04) : A1222 - A1222
  • [23] Effect of CYP3A5 and CYP3A4 Genetic Variants on Fentanyl Pharmacokinetics in a Pediatric Population
    Williams, Michael L.
    Kannankeril, Prince J.
    Breeyear, Joseph H.
    Edwards, Todd L.
    Van Driest, Sara L.
    Choi, Leena
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (04) : 896 - 908
  • [24] CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer
    Zeigler-Johnson, C
    Friebel, T
    Walker, AH
    Wang, YT
    Spangler, E
    Panossian, S
    Patacsil, M
    Aplenc, R
    Wein, AJ
    Malkowicz, SB
    Rebbeck, TR
    CANCER RESEARCH, 2004, 64 (22) : 8461 - 8467
  • [25] Effect of CYP3A5 genotype on the relationship between hepatic CYP3A activity and CYP3A4 and CYP3A5 mRNA expression
    Kolwankar, D
    Ho, H
    Ethell, B
    Vuppalanchi, R
    Marri, SR
    Wrighton, SA
    Jones, DR
    Hall, SD
    DRUG METABOLISM REVIEWS, 2004, 36 : 118 - 118
  • [26] USE OF THE CYP3A4 SELECTIVE INHIBITOR CYP3CIDE IN CYP3A5 GENOTYPED CRYOPRESERVED HUMAN HEPATOCYTES TO EXPLORE THE INDIVIDUAL CONTRIBUTION OF CYP3A4 AND CYP3A5 IN DRUG METABOLISM
    Heyward, Scott
    Schultz, Rachel N. V.
    Dennell, Stephen
    DRUG METABOLISM REVIEWS, 2014, 45 : 135 - 136
  • [27] Variability in heteroactivation of carbamazepine metabolism by endogenous steroids: Comparison of CYP3A4 and CYP3A5 response
    Henshall, Jamie
    Galetin, Aleksandra
    Harrison, Anthony
    Houston, J. Brian
    DRUG METABOLISM REVIEWS, 2006, 38 : 110 - 111
  • [28] Variability in heteroactivation of carbamazepine metabolism by endogenous steroids: Comparison of CYP3A4 and CYP3A5 response
    Henshall, Jamie
    Galetin, Aleksandra
    Harrison, Anthony
    Houston, J. Brian
    DRUG METABOLISM REVIEWS, 2006, 38 : 6 - 6
  • [29] Association of CYP3A4, CYP3A5 polymorphisms with lung cancer risk in Bangladeshi population
    Islam, Mohammad Safiqul
    Mostofa, A. G. M.
    Ahmed, Maizbha Uddin
    Bin Sayeed, Muhammad Shahdaat
    Hassan, Md. Rajib
    Hasnat, Abul
    TUMOR BIOLOGY, 2014, 35 (02) : 1671 - 1678
  • [30] Genetic polymorphisms of the CYP3A4, CYP3A5, CYP3A7 and CYP1A2 among the Jordanian population
    Salameh, Ghada
    Al Hadidi, Kamal
    El Khateeb, Mohammad
    ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 2012, 34 (01) : 23 - 33
12345